Directorio

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.

We are doing this study to find out if an experimental drug called XC001 (the study drug) is an effective option for people who have angina that is caused by coronary artery disease. We want to know if the study drug can provide relief when common, approved therapies have failed to do so. The study drug is made using an adenovirus (one of the causes of the common cold). The adenovirus in the study drug is genetically altered so it is able to deliver a protein called VEGF (vascular endothelial growth factor) to the heart and potentially spur the growth of new blood vessels.

We are doing this study to find out if surgically removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing melanoma from coming back in the same area of the lymph node excision. We also want to learn more about the side effects of this type of surgery and how it can impact patients' quality of life.

In this study, people will get a new kind of eye transplant. They'll be randomly chosen (like flipping a coin) to get either a special treated cornea or a regular one. Doctors will check on them for 2 years after the transplant to see how they're doing and to watch for any side effects.

We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.

We are doing this study to find out if an experimental drug called felzartamab (the study drug) is a safe and effective option for people who have had a kidney transplant and are experiencing antibody-mediated rejection (AMR). We want to know if this drug provides any helpful benefit.

We are doing this study to find out if an experimental drug called LY4337713 (the study drug) is a safe and effective option for people who have FAP-positive solid tumors. The study drug is a type of radiotherapy that is intended to target and attach only to FAP. The goal of targeted radiotherapy is to provide selective delivery of radiation doses that can destroy tumor cells.